Press Releases

Date Title  
Toggle Summary Aimmune Therapeutics Appoints Dr. Jayson Dallas as CEO
— Experienced Leader Brings Extensive Record of Global Strategic and Commercial Operational Accomplishments and Successful Product Launches — BRISBANE, Calif. --(BUSINESS WIRE)--Jun. 11, 2018-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for
Toggle Summary Aimmune Therapeutics Announces New Pan-European Study Showing Significant Psychosocial Burden Associated With Peanut Allergy
— European APPEAL ( A llergy to P eanuts Im p acting E motions a nd L ife) Study Finds Peanut Allergy Has a Daily Impact on More than 80% of People with Peanut Allergy and Parents or Caregivers of Peanut-Allergic Minors — — Data Discussed at EAACI 2018 Reveal Uncertainty, Bullying and High Levels
Toggle Summary Aimmune Therapeutics Announces Data on Terminology Used with Oral Immunotherapy Were Presented at EAACI 2018
— In U.S. Survey , Allergists Want Consensus in Oral Immunotherapy Terminology — — U.S. Allergists Preferred “Tolerated Dose” as the Most Clinically Relevant Term to Communicate Desensitization Levels to Oral Immunotherapy Patients — BRISBANE, Calif. & MUNICH, Germany --(BUSINESS WIRE)--May 29,
Toggle Summary Aimmune Therapeutics Announces New Clinical Data on AR101 for Peanut Allergy at the 2018 EAACI Congress
New analyses including adults enrolled in the Phase 3 PALISADE trial of AR101 show efficacy across the entire intent-to-treat population of peanut-allergic patients ages 4-55 New immunologic subset analyses show that AR101 treatment was linked to depletion of peanut-specific TH2A cells believed to
Toggle Summary Aimmune Therapeutics to Present Data on Peanut Allergy at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2018
— Late-Breaking Oral Presentations on AR101 Phase 3 PALISADE Results in Peanut-Allergic Children and Adults and on European Study of Psychosocial Impact of Peanut Allergy — BRISBANE, Calif. --(BUSINESS WIRE)--May 15, 2018-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company
Toggle Summary Aimmune Therapeutics to Participate in Four Upcoming Investor Conferences in May and June
BRISBANE, Calif. --(BUSINESS WIRE)--May 9, 2018-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of the Aimmune executive management team will participate in four upcoming investor
Toggle Summary Aimmune Therapeutics Announces First Quarter 2018 Financial Results
BRISBANE, Calif. --(BUSINESS WIRE)--May 8, 2018-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced financial results for the first quarter 2018. As of March 31, 2018 , cash, cash equivalents and
Toggle Summary Aimmune Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results
Company began 2018 with approximately $182 Million in cash and investments Pro-forma year-end 2017 cash and investments of approximately $372 Million , including net proceeds from the recently completed public offering Announced over-enrollment in the ARTEMIS Phase 3 trial Additional AR101 clinical
Toggle Summary Aimmune Therapeutics to Participate in Four Investor Conferences in March
BRISBANE, Calif. --(BUSINESS WIRE)--Mar. 7, 2018-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of the Aimmune executive management team will participate in four upcoming investor
Toggle Summary Aimmune Therapeutics Presents Results From the Positive, Pivotal Phase 3 PALISADE Trial of AR101 for Peanut Allergy at AAAAI-WAO
— Late-Breaking Oral Presentation by Dr. Stacie Jones — — PALISADE Results Expected to Provide Core Element of BLA Submission by Year-End 2018 — BRISBANE, Calif. & ORLANDO, Fla. --(BUSINESS WIRE)--Mar. 4, 2018-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing